These data indicate that the phosphorylation of STAT1 is impaired in CD4+ T cells and CD56hi and CD56low NK cell subsets in response to IL-2 treatment and this defect is age-related but not likely due to a reduced proportion of total cells exhibited STAT1 activation in metastatic melanoma patients. The gene discussed is CD4; the disease is metastatic melanoma.